Physician profile
Anas Alsadi
NPI 1881841013
$5,771.98
in general payments reported to CMS, 2019-2025
33 companies · $1,693 in 2025
The $1,693 reported for 2025 was more than what 85% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $39.17 · 2021: $157 · 2022: $219 · 2023: $1,660 · 2024: $1,829 · 2025: $1,693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,018 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,017.76 |
| Education | $163.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,581.34 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,174.04 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $422.21 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $293.61 | 2021-2025 | Glassia |
| Genzyme Corporation | $275.99 | 2023-2025 | |
| Grifols USA, LLC | $238.80 | 2023-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.08 | 2020-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Mylan Specialty L.P. | $182.68 | 2019-2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $163.98 | 2024-2025 | |
| United Therapeutics Corporation | $161.91 | 2023-2025 | Tyvaso, Tyvaso |
| Abbvie INC. | $152.28 | 2021-2024 | Teflaro |
| Insmed, INC. | $128.75 | 2023-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $99.07 | 2022-2024 | Zerbaxa, Recarbrio, Dificid |
| Sunovion Pharmaceuticals INC. | $73.95 | 2019 | |
| Mallinckrodt Hospital Products INC. | $63.66 | 2024-2025 | Acthar |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $63.05 | 2023-2024 | (Ak6) Vest Therapy |
| Pfizer INC. | $57.72 | 2024-2025 | |
| Amgen INC. | $53.16 | 2024-2025 | Tavneos, Tezspire |
| Actelion Pharmaceuticals US, INC. | $46.91 | 2025 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $37.11 | 2022-2023 | Xarelto |
| Ani Pharmaceuticals, INC. | $35.15 | 2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $33.99 | 2023-2025 | |
| Gilead Sciences, INC. | $29.77 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $28.89 | 2023-2024 | Eliquis |
| Viatris Specialty LLC | $28.35 | 2025 | Yupelri |
| Abbott Laboratories | $23.82 | 2022 | |
| Novo Nordisk INC | $20.73 | 2022 | |
| Pharming Healthcare, INC. | $19.70 | 2023 | Ruconest |
| Inogen, INC. | $17.83 | 2025 | |
| Pulmonx Corporation | $17.50 | 2023 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Inspire Medical Systems, INC. | $17.42 | 2025 | Inspire |
| Verona Pharma, INC. | $16.31 | 2025 | Ohtuvayre |
| Baxter Healthcare | $14.22 | 2025 | Hillrom - Monarch Airway Clearance System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anas Alsadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.